Compare Recursion Pharmaceuticals Inc (RXRX) vs Advanced Drainage Systems Inc (WMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Advanced Drainage Systems Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while Advanced Drainage Systems Inc trades at $125.56 (market cap $9.51B). The key difference: Advanced Drainage Systems Inc is far larger — about 4.1× Recursion Pharmaceuticals Inc's market cap, and Advanced Drainage Systems Inc pays a 0.63% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Advanced Drainage Systems Inc for 43 Days on average.
| RXRX | WMS | |
|---|---|---|
Market Cap | $2.31B | $9.51B |
Volume | 40,478,768 | 771,064 |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $175.38 |
52-Week Low | $2.84 | $125.33 |
Typical Hold Time | 22 Days | 43 Days |
Enterprise Value | $1.83B | $11.11B |
Dividend Yield | — | 0.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Advanced Drainage Systems (WMS) trades at $126.21, down 2.97% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin. Recent news includes the release of its 2026 Sustainability Report and a quarterly dividend declaration.
The outlook is mixed; analyst consensus targets $188.70, implying significant upside, but near-term technical pressure and a projected net cash outflow in 2026 present risks. Investment appeal hinges on execution of growth initiatives and margin stability against macroeconomic and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Advanced Drainage Systems Inc
Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →
